{"id":5877,"date":"2024-02-15T01:23:16","date_gmt":"2024-02-15T01:23:16","guid":{"rendered":"https:\/\/economicherald.net\/?p=5877"},"modified":"2024-02-15T01:23:16","modified_gmt":"2024-02-15T01:23:16","slug":"asx-health-stocks-claritys-imaging-agent-can-identify-prostate-cancer-lesions-at-double-the-rate","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=5877","title":{"rendered":"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate"},"content":{"rendered":"<p>Clarity says initial data from Phase 1\/2 trial is positive<br \/>\nOpthea completes enrolment of all patients in the COAST Phase 3 trial<br \/>\nProMedicus locks in record half<\/p>\n<p>\u00a0<\/p>\n<h2>Clarity\u2019s Phase 1\/2 trial shows positive initial results<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/clarity-pharmaceuticals-cu6\/\">Clarity Pharmaceuticals (ASX:CU6)<\/a><\/strong> says that initial data from its <strong>Phase 1\/2 trial<\/strong> has confirmed that <strong>64Cu-SAR-bisPSMA<\/strong> is safe and highly effective in detecting <strong>prostate cancer (PC) lesions<\/strong> in patients with <strong>biochemical recurrence (BCR).<\/strong><\/p>\n<p>64Cu- SAR-bisPSMA is a copper-based imaging agent. It contains copper-64 (64Cu), and is used to visualise tumors that express the PSMA protein using a positron emission tomography (PET) scanner.<\/p>\n<p>The Phase 1\/2 trial, also called <strong>COBRA<\/strong>, is studying PC lesions in patients with BCR where standard of care imaging was unable to detect any lesions.<\/p>\n<p>Initial data suggests that, when 64Cu-SAR-bisPSMA is used, up to approximately 60% had lesions identified by same-day 64Cu-SAR-bisPSMA imaging, and up to 80% on next- day imaging, with high specificity on both days.<\/p>\n<p>The next day imaging increases detections from 80 on Day 0 to up to 153 lesions on Day 1.<\/p>\n<p>Clarity describes the almost doubling of the number of lesions with next-day imaging as remarkable, and brings to light the issues of current standard of care imaging.<\/p>\n<p>\u201cCurrent standard of care imaging fails to do this for a large percentage of men who eventually experience BCR of their PC,\u201d said Clarity\u2019s executive chair, Dr Alan Taylor.<\/p>\n<p>\u201cAs such, there is an immediate opportunity for bisPSMA to address the entire market of PSMA imaging as we move closer to our ultimate goal of improving treatment outcomes of people with cancer.\u201d<\/p>\n<p>Following the results from 64Cu-SAR-bisPSMA PET imaging, investigators of the trial indicated that they would change the treatment plan of approximately half of the patients (48%) to use 64Cu-SAR-bisPSMA.<\/p>\n<p>Initial results from the COBRA trial will be presented at leading international oncology and nuclear medicine conferences.<\/p>\n<p>\u00a0<\/p>\n<h2>Opthea completes Phase 3 enrolment<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/opthea-opt\/\">Opthea (ASX:OPT)<\/a><\/strong> has completed enrolment of all patients in the <strong>COAST Phase 3 pivotal clinical trial<\/strong> investigating <strong>sozinibercept (OPT-302)<\/strong>, in combination with aflibercept, a well known therapy for <strong>wet Age-related Macular Degeneration (wet AMD).<\/strong><\/p>\n<p>OPT-302 is Opthea\u2019s novel recombinant \u201ctrap\u201d fusion protein, which inhibits vascular endothelial growth factor <strong>(VEGF)-C<\/strong> and <strong>VEGF-D<\/strong> \u2013 two factors demonstrated to be important in the molecular pathogenesis of tumour growth associated with several blinding eye diseases.<\/p>\n<p>The sozinibercept clinical program includes two Phase 3 pivotal trials, <em>COAST and ShORe.<\/em>\u00a0Enrolment in ShORe is expected to be completed in calendar Q2 this year.<\/p>\n<p>Earlier, Phase 2b study of sozinibercept when combined with <em>ranibizumamet<\/em> had met its pre-specified primary efficacy endpoint.<\/p>\n<p>\u00a0<\/p>\n<h2>ProMedicus locks in record half<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/promedicus-pme\/\">ProMedicus (ASX:PME)<\/a><\/strong> announced a half-year net profit of $36.3 million for the six months to the end of December, 33.3% higher than the pcp.<\/p>\n<p>This was on the back of revenue of $74.1 million, up 30.3% on pcp.<\/p>\n<p>This was a record half for the company in terms of revenue and net profit, as well as new sales.<\/p>\n<p>ProMedicus announced a fully-franked interim dividend of 18c per share.<\/p>\n<p>The company remains debt-free, and says its pipeline is strong across all sectors of the market.<\/p>\n<p>ProMedicus is a leading healthcare informatics company. Its medical imaging software are used in hospitals and imaging centres worldwide.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-claritys-imaging-agent-can-identify-prostate-cancer-lesions-at-double-the-rate\/\">ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Clarity says initial data from Phase 1\/2 trial is positive Opthea completes enrolment of all patients in the COAST Phase 3 trial ProMedicus locks in <a href=\"https:\/\/economicherald.net\/?p=5877\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":5878,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-5877","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=5877\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Clarity says initial data from Phase 1\/2 trial is positive Opthea completes enrolment of all patients in the COAST Phase 3 trial ProMedicus locks in [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=5877\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-15T01:23:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate\",\"datePublished\":\"2024-02-15T01:23:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877\"},\"wordCount\":565,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Clarity-says-initial-data-from-Phase-12-trial-is-positive.-Picture-Getty-mKlhF2.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=5877\",\"name\":\"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Clarity-says-initial-data-from-Phase-12-trial-is-positive.-Picture-Getty-mKlhF2.jpeg\",\"datePublished\":\"2024-02-15T01:23:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5877\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Clarity-says-initial-data-from-Phase-12-trial-is-positive.-Picture-Getty-mKlhF2.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Clarity-says-initial-data-from-Phase-12-trial-is-positive.-Picture-Getty-mKlhF2.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5877#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=5877","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate - Economic Herald","og_description":"Clarity says initial data from Phase 1\/2 trial is positive Opthea completes enrolment of all patients in the COAST Phase 3 trial ProMedicus locks in [more...]","og_url":"https:\/\/economicherald.net\/?p=5877","og_site_name":"Economic Herald","article_published_time":"2024-02-15T01:23:16+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=5877#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=5877"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate","datePublished":"2024-02-15T01:23:16+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=5877"},"wordCount":565,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=5877#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Clarity-says-initial-data-from-Phase-12-trial-is-positive.-Picture-Getty-mKlhF2.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=5877","url":"https:\/\/economicherald.net\/?p=5877","name":"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=5877#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=5877#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Clarity-says-initial-data-from-Phase-12-trial-is-positive.-Picture-Getty-mKlhF2.jpeg","datePublished":"2024-02-15T01:23:16+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=5877#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=5877"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=5877#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Clarity-says-initial-data-from-Phase-12-trial-is-positive.-Picture-Getty-mKlhF2.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Clarity-says-initial-data-from-Phase-12-trial-is-positive.-Picture-Getty-mKlhF2.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=5877#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Clarity\u2019s imaging agent can identify prostate cancer lesions at double the rate"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5877"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5877\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/5878"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}